PDF(Pubmed)
Abstract：
Despite several improvements in outcomes, metastatic prostate cancer remains deadly. Alterations in the homologous recombination repair (HRR) pathway are associated with more aggressive disease. Olaparib and rucaparib, two poly-ADP-ribose polymerase (PARP) inhibitors, have received approval from the authorities of several countries for their anti-tumoral effects in patients with metastatic castration-resistant prostate cancers harboring HRR gene alterations, in particular BRCA2. More recently, it has been hypothesized that new hormonal therapies (NHTs) and PARP inhibitors (PARPi) could have synergistic actions and act independently of HRR deficiency. This review proposes to discuss the advantages and disadvantages of PARPi used as monotherapy or in combination with NHTs and whether there is a need for molecular selection.
摘要：
尽管结果有所改善，转移性前列腺癌仍然是致命的.同源重组修复(HRR)途径的改变与更具侵袭性的疾病相关。Olaparib和rucaparib,两种聚ADP-核糖聚合酶（PARP）抑制剂，已经获得了几个国家当局的批准，因为它们对具有HRR基因改变的转移性去势抵抗性前列腺癌患者的抗肿瘤作用，特别是BRCA2。最近,据推测,新的激素疗法(NHTs)和PARP抑制剂(PARPi)可能具有协同作用,且作用独立于HRR缺乏.这篇综述建议讨论PARPi用作单一疗法或与NHT联合使用的优缺点，以及是否需要进行分子选择。
